Clinical trials: Attention-deficit Hyperactivity Disorder (ADHD)
ADHD, Attention Deficit Hyperactivity Disorder
Study of Medication Patch to Treat Children Ages 6-12 With ADHD
The purpose of this study is to investigate the effectiveness of a medication skin patch called Methylphenidate Transdermal System (MTS). We will compare the MTS medicated patch to a placebo patch.
- Trial name
- NCT00586157
- Testing
- Methylphenidate Transdermal System
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
ADHD, Attention Deficit Hyperactivity Disorder
Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of atomoxetine and OROS methylphenidate, taken together, in the treatment of ADHD in children and adolescents ages 6-17.
- Trial name
- NCT00585910
- Testing
- Atomoxetine and OROS Methylphenidate
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Hyperactivity Disorder (ADHD)
Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults
The purpose of this research study is to learn about the effects of a medication called Vyvanse on the heart (cardiovascular system). The U.S.
- Trial name
- NCT00753012
- Testing
- Lisdexamfetamine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
ADHD, Smoking
Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The objective of this study is to evaluate whether Osmotic-Release Methylphenidate (OROS MPH), relative to placebo, increases the effectiveness of standard smoking treatment (i.e., nicotine patch and individual smoking cessation…
- Trial name
- NCT00253747
- Testing
- Osmotic-Release Methylphenidate
- Where
- 6 sites in United States
- Volunteers
- 255 people
- Sponsor
- University of Cincinnati
ADHD
Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate
This will be an open label study using daily does of up to 126mg/day of Concerta in the treatment of children and adolescents, ages 12-17, who meet DSM-IV criteria for ADHD.
- Trial name
- NCT00593112
- Testing
- OROS methylphenidate, No intervention
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
ADHD
Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS
The primary objective of the study is to assess the efficacy and tolerability of a 12-week trial of memantine hydrochloride administered twice daily in 20 adults (ages 18-55) with ADHD and ADHD NOS.
- Trial name
- NCT00586573
- Testing
- memantine hydrochloride
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
ADHD
Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate efficacy, safety and tolerability of metadoxine (MG01CI) extended release formulation for the treatment of adults diagnosed with ADHD
- Trial name
- NCT01243242
- Testing
- Metadoxine (MG01CI)
- Where
- 2 sites in Israel
- Volunteers
- 120 people
- Sponsor
- Alcobra Ltd.
ADHD
The Reinforcing Mechanisms of Smoking in Adult ADHD
Whereas the smoking prevalence rates in the general population are declining, rates among people diagnosed with attention-deficit hyperactivity disorder (ADHD) continue to be elevated.
- Trial name
- NCT00573859
- Testing
- ADHD medication
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, Irvine
ADHD
Nicotine and Behavior in Adult ADHD
Attention deficit hyperactivity disorder (ADHD) is characterized by inattention, impulsivity, and hyperactivity that are frequently treated with stimulant medications such as Ritalin. Many people with ADHD smoke.
- Trial name
- NCT00573248
- Testing
- Nicotine
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- University of California, Irvine
Attention-Deficit/Hyperactivity Disorder (ADHD)
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
This study will evaluate the efficacy and safety of Dex-Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6-12 with Attention-Deficit Hyperactivity Disorder (ADHD) in a 12-hour laboratory…
- Trial name
- NCT00776009
- Testing
- Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)
- Where
- 8 sites in United States
- Volunteers
- 165 people
- Sponsor
- Novartis Pharmaceuticals